NeuroRegen Scaffold™ With Stem Cells for Chronic Spinal Cord Injury Repair
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02352077|
Recruitment Status : Unknown
Verified October 2016 by Jianwu Dai, Chinese Academy of Sciences.
Recruitment status was: Enrolling by invitation
First Posted : February 2, 2015
Last Update Posted : December 23, 2020
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Spinal Cord Injury||Biological: NeuroRegen scaffold with BMMCs or MSCs transplantation||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Safety and Efficacy of NeuroRegen Scaffold™ With Bone Marrow Mononuclear Cells or Mesenchymal Stem Cells for Chronic Spinal Cord Injury Repair|
|Study Start Date :||January 2015|
|Estimated Primary Completion Date :||December 2021|
|Estimated Study Completion Date :||December 2021|
|Experimental: NeuroRegen Scaffold with BMMCs or MSCs transplantation||
Biological: NeuroRegen scaffold with BMMCs or MSCs transplantation
Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with bone marrow mononuclear cells (BMMCs) or mesenchymal stem cells (MSCs) transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
- Safety Evaluation Number of patients with adverse events [ Time Frame: 6 months ]Number of patients with adverse events is as a measure of safety and tolerability after collagen scaffold with MSCs transplantation.
- Improvements in Neurophysiological Measures omatosensory Evoked Potentials (SSEP) and Motor Evoked Potentials (MEP) monitoring will be assessed [ Time Frame: 12 months ]Somatosensory Evoked Potentials (SSEP) and Motor Evoked Potentials (MEP) monitoring will be assessed before and after transplantation.
- Improvements in ASIA Impairment Scale [ Time Frame: 12 months ]American Spinal Injury Assessment Scale of A, B, C, D or E will be assessed before and after transplantation.
- Improvements in Independence Measures and Quality of Life [ Time Frame: 12 months ]Functional Independence Measure (FIM) and the Quality of Life Questionnaire (EQ 5D) will be assessed before and after transplantation.
- Improvements in Pain assessed based on Visual analog scale (VAS) [ Time Frame: 12 months ]Pain intensity will be assessed based on Visual analog scale (VAS) before and after transplantation.
- Improvements in Urinary and Bowel Function assessed based on bladder pressure monitory before and after transplantation [ Time Frame: 12 months ]The ability to feel and control urination and bowel will be assessed based on bladder pressure monitory before and after transplantation.
- Changes at the Transplantation Site in Spinal Cord by Magnetic Resonance Imaging (MRI) [ Time Frame: 12 months ]The MRI at the transplantation site will be assessed before and after transplantation.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 65 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Male or female, 18-65 years old.
- Completely spinal cord injury at the cervical and thoracic level (C5-T12).
- Classification ASIA A with no significant further improvement.
- Patients signed informed consent.
- Ability and willingness to regular visit to hospital and follow up during the protocol Procedures.
- A current diagnosis of any primary diseases affecting limb functions (e.g., trauma, infection, tumors, congenital malformations, peripheral muscular dystrophy, Huntington's disease, Parkinson's disease).
- Serious complications (e.g., hydronephrosis due to renal insufficiency, severe bedsores (Ⅲ° above), lower extremity venous thrombosis, severe myositis ossificans).
- History of life threatening allergic or immune-mediated reaction.
- Clinically significant abnormalities in routine laboratory examinations (hematology, electrolytes, biochemistry, liver and kidney function tests, urinanalysis).
- History of mental illness or suicide risk, with a history of epilepsy or other central nervous system disorders.
- Severe arrhythmias (e.g., ventricular tachycardia, frequent superventricular tachycardia, atrial fibrillation, and atrial flutter) or cardiac degree II or above conduction abnormalities displayed via 12-lead ECG.
- Lactating and pregnant woman.
- Alcohol drug abuse /dependence.
- Participated in any other clinical trials within 3 months before the enrollment.
- A drug or treatment known to cause effect on the central nervous system during the past four weeks.
- A drug or treatment known to cause major organ system toxicity during the past four weeks.
- Poor compliance, difficult to complete the study.
- Any other conditions that might increase the risk of subjects or interfere with the clinical trial.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02352077
|First Hospitals affiliated to the China PLA General Hospital|
|Beijing, China, 100037|
|The First Affiliated Hospital of Soochow University|
|Suzhou, China, 215006|
|Affiliated Hospital of Logistics Universtiy of CAPF|
|Tianjin, China, 300162|
|Principal Investigator:||Jianwu Dai, Ph.D||Chinese Academy of Sciences|
|Study Chair:||Sai Zhang, M.D||Affiliated Hospital of Logistics Universtiy of CAPF|
|Study Chair:||Huilin Yang, Ph.D||The First Affiliated Hospital of Soochow University|
|Study Chair:||Shuxun Hou||First Hospitals affiliated to the China PLA General Hospital|
|Responsible Party:||Jianwu Dai, Principal Investigator of Regenerative Medicine Laboratory, Institute of Genetics and Developmental Biology, CAS, Chinese Academy of Sciences|
|Other Study ID Numbers:||
|First Posted:||February 2, 2015 Key Record Dates|
|Last Update Posted:||December 23, 2020|
|Last Verified:||October 2016|
Spinal Cord Injuries
Wounds and Injuries
Spinal Cord Diseases
Central Nervous System Diseases
Nervous System Diseases
Trauma, Nervous System